Results for &quot;&quot;Diethylpropion&quot;&quot;[mesh_terms]

Obesity in adults.

David Delaet, Daniel Schauer

BMJ clinical evidence 2016;2011():0604

Weight loss medications--where do they fit in?

John B Dixon

Australian family physician 2006;35(8):576-9

Obesity.

David Flum, David Arterburn, David DeLaet

Clinical evidence 2006

Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients.

Rosa Camila Lucchetta, Bruno Salgado Riveros, Roberto Pontarolo, Rosana Bento Radominski, Michel Fleith Otuki, Fernando Fernandez-Llimos, Cassyano Januário Correr

Clinics (Sao Paulo, Brazil) 2017;72(5):317-324

Obesity.

David Arterburn

Clinical evidence 2005

Pharmacological and surgical treatment of obesity.

P G Shekelle, S C Morton, M Maglione, M Suttorp, W Tu, Z Li, M Maggard, W A Mojica, L Shugarman, V Solomon

Evidence report/technology assessment (Summary) 2004

A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects.

C Cercato, V A Roizenblatt, C C Leança, A Segal, A P Lopes Filho, M C Mancini, A Halpern

International journal of obesity (2005) 2010;33(8):857-65

Pharmacogenetics of amfepramone in healthy Mexican subjects reveals potential markers for tailoring pharmacotherapy of obesity: results of a randomised trial.

Magdalena Gómez-Silva, Everardo Piñeyro-Garza, Rigoberto Vargas-Zapata, María Elena Gamino-Peña, Armando León-García, Mario Bermúdez de León, Adrián Llerena, Rafael B R León-Cachón

Scientific reports 2020;9(1):17833

A comparative study of five centrally acting drugs on the pharmacological treatment of obesity.

R Radominski, C L Boguszewski, C M C dos Santos, M do Desterro de Figueiredo, D R Cunha, H Suplicy

International journal of obesity (2005) 2015;38(8):1097-103

Six-month efficacy and safety of amfepramone in obese Mexican patients: a double-blinded, randomized, controlled trial.

Herman Soto-Molina, Mariel Pizarro-Castellanos, Juana Rosado-Pérez, Antonio Rizzoli-Córdoba, Eleazar Lara-Padilla, Cecilia Fernández del Valle-Laisequilla, Juan Gerardo Reyes-García

International journal of clinical pharmacology and therapeutics 2015;53(7):541-9

Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation.

M J Abramowicz, P Van Haecke, M Demedts, M Delcroix

The European respiratory journal 2004;22(3):560-2

Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety.

G Glazer

Archives of internal medicine 2001;161(15):1814-24